

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

REQUEST FOR ACCESS TO AN ABANDONED APPLICATION UNDER 37 CFR 1.14

Bring completed form to:
File Information Unit
Crystal Plaza Three, Room 1D01
2021 South Clark Place
Arlington, VA
Telephone: (703) 308-2733

File Information Unit	2021-24-2005
File Information Unit	

In re Application of

Application Number	087612,929	Filed	4/30/96
--------------------	------------	-------	---------

Paper No. 22

I hereby request access under 37 CFR 1.14(a)(1)(iv) to the application file record of the above-identified ABANDONED application, which is identified in, or to which a benefit is claimed, in the following document (as shown in the attachment):

United States Patent Application Publication No. _____, page, _____ line _____.

United States Patent Number 2005/0002959, column _____, line, _____ or

WIPO Pub. No. _____, page _____, line _____.

Related Information about Access to Pending Applications (37 CFR 1.14):

Direct access to pending applications is not available to the public but copies may be available and may be purchased from the Office of Public Records upon payment of the appropriate fee (37 CFR 1.19(b)), as follows:

For published applications that are still pending, a member of the public may obtain a copy of:

- the file contents;
- the pending application as originally filed; or
- any document in the file of the pending application.

For unpublished applications that are still pending:

- (1) If the benefit of the pending application is claimed under 35 U.S.C. 119(e), 120, 121, or 365 in another application that has: (a) issued as a U.S. patent, or (b) published as a statutory invention registration, a U.S. patent application publication, or an international patent application publication in accordance with PCT Article 21(2), a member of the public may obtain a copy of:
 - the file contents;
 - the pending application as originally filed; or
 - any document in the file of the pending application.
- (2) If the application is incorporated by reference or otherwise identified in a U.S. patent, a statutory invention registration, a U.S. patent application publication, or an international patent application publication in accordance with PCT Article 21(2), a member of the public may obtain a copy of:
 - the pending application as originally filed.

Arieb Tesfey

Signature

Arieb Tesfey

Typed or printed name

10/24/05

Date

FOR PTO USE ONLY	
Approved by:	<u>A. T.</u> (initials)
File Information Unit	

Registration Number, if applicable

703-486-1150

Telephone Number



US 20050002959A1

(19) **United States**

(12) **Patent Application Publication** (10) **Pub. No.: US 2005/0002959 A1**

Holmes et al.

(43) **Pub. Date:** **Jan. 6, 2005**

(54) **RECOMBINANT IL4 ANTIBODIES USEFUL
IN TREATMENT OF IL4 MEDIATED
DISORDERS**

(75) Inventors: **Stephen Dudley Holmes**, Epsom (GB);
Mitchell Stuart Gross, Wayne, PA
(US); **Daniel R. Sylvester**,
Phoenixville, PA (US)

Correspondence Address:
GLAXOSMITHKLINE
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, PA 19406-0939 (US)

(73) Assignees: **SmithKline Beecham p.l.c.; SmithKline
Beecham Corporation**

(21) Appl. No.: **10/723,872**

(22) Filed: **Nov. 26, 2003**

Related U.S. Application Data

(63) Continuation of application No. 09/879,461, filed on Jun. 12, 2001, now abandoned, which is a continuation of application No. 09/426,814, filed on Oct. 22, 1999, now abandoned, which is a continuation of application No. 08/612,929, filed on Apr. 30, 1996, now abandoned, filed as 371 of international application No. PCT/US94/10308, filed on Sep. 7, 1994, which is a continuation-in-part of application No. 08/136,783, filed on Oct. 14, 1993, now abandoned, which is a continuation of application No. 08/117,366, filed on Sep. 7, 1993, now abandoned.

Publication Classification

(51) **Int. Cl.⁷** **A61K 39/00; C12P 21/04;**
C07K 16/46

(52) **U.S. Cl.** **424/192.1; 435/69.7; 530/350;**
530/391.1

(57) **ABSTRACT**

Chimeric and humanized IL4 MAbs derived from affinity MAbs, pharmaceutical compositions containing same, and methods of treatment are provided.